openPR Logo
Press release

Aquigen Bio Introduces N‐Nitroso Pirfenidone EP Impurity B - A High-Purity Reference Standard for Pharmaceutical Analysis, Method Validation, and Regulatory Compliance in Pirfenidone Impurity Profiling

08-07-2025 02:45 PM CET | Health & Medicine

Press release from: Aquigen Bio Sciences

Aquigen Bio Introduces N‐Nitroso Pirfenidone EP Impurity B -

Pune-/Delran- Aquigen Bio is pleased to announce the introduction of N‐Nitroso Pirfenidone EP Impurity B, a premium reference standard designed for the highest rigor in pharmaceutical analysis and regulatory compliance. Available via custom‐synthesis, this product serves as an essential resource for analytical method development (AMD), method validation (AMV), quality control (QC), and support for Abbreviated New Drug Applications (ANDA)

https://aquigenbio.com/product/n-nitroso-pirfenidone-ep-impurity-b/
Product Highlights

Name: N‐Nitroso Pirfenidone EP Impurity B
Catalog No: AQ‐N000968
CAS No: 2512237‐43‐1
Molecular Formula: C6H6N2O2
Molecular Weight: 138.1
Chemical Name: 5‐methyl‐1‐nitrosopyridin‐2(1H)‐one
Availability: Custom synthesis, ready to dispatch within 24 hours (backorder)
Application: Ideal analytical standard with traceability to pharmacopeial references (USP/EP), used in regulatory submissions and lab QC processes.

Why This Matters
Analytical precision has never been more critical. Regulatory agencies demand exact identification and quantification of impurities-especially nitrosamines, classed as potentially carcinogenic. N‐Nitroso Pirfenidone EP Impurity B delivers:
Confidence in method validation and QC through consistent, character‐verified standards.

Compliance with global regulatory guidelines, thanks to full documentation and traceability potential.
Efficiency by offering ready availability and streamlined logistics.
Aquigen Bio underscores that this product is strictly for analytical use and not intended for human consumption.

Safety & Handling
Your safety is paramount. To ensure responsible laboratory use, Aquigen Bio provides extensive guidelines, including:
Review of the Safety Data Sheet (SDS) for crucial handling instructions.
Use of appropriate Personal Protective Equipment (PPE)-like gloves, goggles, respirators, and lab coats.
Conducting procedures in well‐ventilated areas, such as fume hoods or controlled environments.
Proper labeling and storage to avoid contamination.
Adhering to local disposal laws for hazardous chemical waste.
Providing adequate training, emergency response, and incident reporting protocols.
These practices help maintain high safety standards in labs utilizing this impurity standard.

Related Category: Pirfenidone Impurity Standards
As part of Aquigen Bio's broader Pirfenidone impurity standards collection, this product is grouped under the Impurity Standards → Pirfenidone category, which includes a wide portfolio of pharmacopoeial reference compounds Aquigen Bio. You can explore additional related products here:

Category Link: Impurity Standards - Pirfenidone- AquigenBio
https://aquigenbio.com/products/impurity-standards/pirfenidone/

Product: N‐Nitroso Pirfenidone EP Impurity A
Complementing Impurity B, Aquigen also provides N‐Nitroso Pirfenidone EP Impurity A,
offering versatility for broader analytical profiling:

Catalog No: AQ‐N000969
CAS No: 126209‐21‐0
Molecular Formula: C6H7N3O
Molecular Weight: 137.1
Chemical Name: N‐(5‐methylpyridin‐2‐yl)nitrous amide
Status: Custom‐synthesized, ready to dispatch within 24 hours (backorder)
Use Cases: AMV, QC, ANDA contexts-mirroring the dual‐application nature of Impurity B

Safety: Not for human consumption; full documentation and safety measures provided
This standard allows analytical labs to address multiple impurity forms in Pirfenidone, reinforcing method robustness and regulatory readiness.
How to Request or Order
Aquigen Bio ensures a seamless procurement experience:
Submit an RFQ (Request for Quotation) with details such as quantity (MG, GM, KG), company information, and contact details.

Explore - N‐Nitroso Pirfenidone EP Impurity A
https://aquigenbio.com/product/n-nitroso-pirfenidone-ep-impurity-a/

Benefit from complete documentation, worldwide delivery, and product accuracy assurances
Production is backed by rapid dispatch capability-despite backorder status.

Final Thoughts
In the modern pharmaceutical landscape, analytical accuracy is not optional-it's essential. With N‐Nitroso Pirfenidone EP Impurity B, Aquigen Bio supports lab professionals and regulatory teams with a high‐integrity, well‐characterized impurity standard. Combined with Impurity A, the offering delivers comprehensive support for Pirfenidone impurity profiling.
For more details, documentation, or to initiate a quotation, please visit the list of Pirfenidone impurity standards.

Contact:
Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Phone: +91 7030123794
Email: bd@aquigenbio.com
Visit: www.aquigenbio.com

About Aquigen Bio Sciences
Aquigen Bio Sciences is at the forefront of pharmaceutical excellence, serving as the leading resource for Pirfenione impurity standards in India. With a strong commitment to safety, innovation, and regulatory compliance, the organization specializes in impurity profiling, synthesis, and analysis, empowering pharmaceutical manufacturers globally with premier standards. Aquigen Bio Sciences' dedication to cutting-edge research ensures it remains a trusted partner in refining quality benchmarks across the pharmaceutical landscape.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aquigen Bio Introduces N‐Nitroso Pirfenidone EP Impurity B - A High-Purity Reference Standard for Pharmaceutical Analysis, Method Validation, and Regulatory Compliance in Pirfenidone Impurity Profiling here

News-ID: 4136527 • Views:

More Releases from Aquigen Bio Sciences

Estradiol Valerate EP Impurity A - Premium Reference Standard for Analytical Development, Quality Control, and Regulatory Compliance in Pharmaceutical Research
Estradiol Valerate EP Impurity A - Premium Reference Standard for Analytical Dev …
Estradiol Valerate EP Impurity A is a high-quality reference standard designed to meet the stringent requirements of pharmaceutical research, method validation, and quality control processes. Explore Estradiol Valerate EP Impurity A : https://aquigenbio.com/product/estradiol-valerate-ep-impurity-a/ Manufactured and characterized with precision, this impurity standard supports laboratories and manufacturers in achieving consistent, reliable, and reproducible results in critical analytical workflows. With its exceptional purity and accurate characterization, Estradiol Valerate EP Impurity A plays a vital role
High-Purity N-Nitroso Betahistine D3 for Precise Pharmaceutical Analysis | Deuterated Nitrosamine Impurity Standard for Method Development, Validation, Quality Control, and Regulatory Submissions in Betahistine Impurity Profiling and Research
High-Purity N-Nitroso Betahistine D3 for Precise Pharmaceutical Analysis | Deute …
Product Overview N-Nitroso Betahistine D3 is a premium deuterated nitrosamine impurity standard, specifically developed for precise analytical testing in pharmaceutical laboratories. This reference standard is widely used for analytical method development, validation, and quality control processes to meet stringent regulatory guidelines. With exceptional purity, complete documentation, and reliable traceability, it is ideal for research, development, and compliance applications. https://aquigenbio.com/product/n-nitroso-betahistine-d3/ Key Features and Benefits Deuterated Design for Precision: The incorporation of deuterium improves mass spectrometric
Aquigen Bio Strengthens Pharmaceutical Research with High-Purity Icatibant Impurity Standards
Aquigen Bio Strengthens Pharmaceutical Research with High-Purity Icatibant Impur …
Aquigen Bio, a trusted supplier of pharmaceutical reference standards, today announced the expansion of its Icatibant Impurity Standards portfolio, designed to support drug developers, analytical laboratories, and research organizations with reliable materials for impurity profiling and quality control. Icatibant, a selective bradykinin B2 receptor antagonist, is widely used in the treatment of hereditary angioedema (HAE). Given its peptide-based structure, Icatibant is prone to the formation of impurities during synthesis and storage.
Elevating Analytical Precision with Harmine Impurity Standards
Elevating Analytical Precision with Harmine Impurity Standards
In the realm of pharmaceutical research, controlling the purity of compounds is pivotal. When evaluating psychoactive alkaloids such as harmine-a β-carboline alkaloid known for its reversible monoamine oxidase A inhibition and emerging therapeutic potential-accuracy is non-negotiable. This is where Aquigen Bio Sciences brings its edge: supplying high-grade impurity standards to underpin analytical consistency and regulatory compliance. Why Harmine Impurity Standards Matter https://aquigenbio.com/products/impurity-standards/harmine/ Harmine occurs naturally in Peganum harmala and Banisteriopsis caapi, and has

All 5 Releases


More Releases for Pirfenidone

Bronchiolitis Obliterans Syndrome Pipeline Analysis (2023) Covering Clinical Tri …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Bronchiolitis Obliterans Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Bronchiolitis Obliterans Syndrome Pipeline Insight,
Bronchiolitis Obliterans Syndrome Market to Register Incremental Growth During t …
In 2022, the total market size of Bronchiolitis Obliterans Syndrome (BOS) in the 7MM was approximately USD 58 million, which is expected to rise during the study period (2019-2032). The Bronchiolitis Obliterans Syndrome Market is set to register immense growth in the coming years owing to the increasing BOS cases in the 7MM and the launch of new therapies for BOS. DelveInsight's "Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market
Pirfenidone Market Report- Size Analysis and Prediction by Leading Manufacturers …
The Pirfenidone Market research report highlights market insights with key trends and a breakdown of the Pirfenidone Market. In addition, it provides information about products and offerings and impact due to macroeconomics and Covid-19 impact on the Pirfenidone Market. Qualitative and quantitative insights are evaluated in the research report, and the market size, growth, and share are also included in the research report. Pirfenidone Market also offers analysis and insights
Pirfenidone Market: Generate New Growth Opportunities by 2025 and Top Key Player …
The Pirfenidone market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets and also market competitors. The report estimates the performance of the key players by 2025. Global Pirfenidone Market Overview: The report provides actionable insights to improve source-to-contract cycle performance in the Global
Esbriet (pirfenidone) Market 2020 Clinical Area Segmentation to 2030
Esbriet (pirfenidone) - Drug Insight and Market Forecast – 2030 The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Esbriet (pirfenidone) Market on the basis of stating current situation of the industry in 2020. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect
Pirfenidone Market Dynamics & Future Demands with Production, Cost Structure and …
2018-2025 Pirfenidone Report on United States and Global Market, Status and Forecast, by Players, Types and Applications is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing capital structure of the Pirfenidone Market. Pirfenidone Market Overview: If you are involved in